All News

MELVILLE, New York-InTouch magazine, the Good Health Guide to Cancer Prevention and Treatment, has joined forces with the American Society of Clinical Oncology (ASCO). Beginning with the May 2002 issue, ASCO will contribute a regular page to the magazine, which is published six times a year.

HOLLYWOOD, Florida-There were several significant changes to the National Comprehensive Cancer Network (NCCN) Hodgkin’s disease guidelines announced at the Seventh Annual NCCN Conference.

A number of molecularly targeted agents directed at critical cell survival and cell proliferation pathways have recently entered clinical evaluation in children with cancer. These agents offer the potential for more effective anticancer therapy while simultaneously diminishing acute and long-term toxic effects. Systematic evaluations of targeted agents are essential to achieving continued improvements in outcome for children with cancer. Brief summaries of the rationale for conducting studies of several agents in children are provided below. Following these summaries is a listing of phase I, phase I/II, phase II, and pilot studies of these and other agents in pediatric populations.

Although liver cancer has a relatively low incidence in the United States, compared with other cancers, it is 10 times more common in many developing countries than in this country.[1] The incidence of liver cancer is highest in sub-Saharan Africa, China, southern Asia, and Japan.[2]

Dr. Armitage is an experienced investigator in both lymphoma research and marrow/stem cell transplantation. As such, he is ideally suited to comment on the attributes of mitoxantrone (Novantrone) in the treatment of malignant lymphoma.

In their article, Drs. Choi and Billings address a number of strategic areas in palliative care. These topics include the definition and scope of the evolving field, the complexities involved in the use of modalities that carry burden or risk (such as artificial nutrition and bowel decompression), and the underappreciated importance of communication skills and a capacity for ethical reasoning.

Dr. Armitage presents a succinct and thorough review of the role of mitoxantrone (Novantrone) in patients with non-Hodgkin’s lymphoma (NHL). He begins by emphasizing the importance of accurate diagnosis as described in the World Health Organization classification which evolved from the Revised European American Lymphoma classification. Both of these present day classifications are based on the immunologic principles separating lymphomas into B- and T-cell disorders developed in the 1970s by Lennert, Lukes, and Collins.[1,2] His review addresses multiple issues in mitoxantrone therapy, including dose intensity, cardiotoxicity, combination therapy with nucleoside analogs in low-grade lymphomas, the impact of rituximab (Rituxan), therapy for acquired immunodeficiency syndrome (AIDS)-related lymphoma, and the role of high-dose mitoxantrone as part of a preparative regimen for autologous transplants.

In the United States, hospice and palliative care are two distinct expressions of the hospice interdisciplinary team approach to end-of-life care, which originated in Great Britain in the 1960s. The hospice movement developed largely as a home-care program and alternative to conventional care.

The introduction of highly active antiretroviral therapy (HAART) has had a dramatic impact on the morbidity and mortality of individuals living with human immunodeficiency virus (HIV). In addition to contributing to declines in the incidence of several opportunistic infections, HAART is affecting the incidences of several acquired immunodeficiency syndrome (AIDS)-defining malignancies.

The development of doxorubicin was an important advance in the treatment of patients with non-Hodgkin’s lymphoma (NHL). Alternatives to doxorubicin, such as mitoxantrone (Novantrone), have less nonhematologic toxicity and could offer a therapeutic advantage in some situations if similar antilymphoma activity exists. Several combination regimens that include mitoxantrone have been shown to be active.

WASHINGTON-Senator John Breaux and Congresswoman Donna Christianson, speaking at the National Patient Advocate Foundation’s Patient Congress III, called for comprehensive, available health care and health insurance for all, regardless of age, income, or employment status.

Front-line treatment for previously untreated follicular B-cell lymphoma with the iodine-131-labeled anti-CD20 antibody tositumomab (Bexxar) has been reported to result in a 97% response rate and a 74% complete response rate.

WASHINGTON-President Bush’s proposed new budget for the National Institutes of Health (NIH), if enacted by Congress, would complete the 5-year, bipartisan effort to double the agency’s budget over 5 years.

CHICAGO-Computer-aided detection (CAD) has been shown to improve the identification of breast malignancies on film-based mammography in studies involving large databases of films, said Kathryn O’Shaughnessy, PhD, director of clinical and regulatory affairs, R2 Technology, Inc., Los Altos, California. Now, the method has been shown to be equally accurate in the analysis of full-field digital mammography images, she said at the 87th Scientific Assembly and Annual Meeting of the Radiological Society of North America (abstract 995).

ORLANDO-About one third of "bad prognosis" refractory B-cell chronic lymphocytic leukemia (B-CLL) patients are salvageable with alemtuzumab (Campath-1H), according to a compassionate use study presented at the 43rd Annual Meeting of the American Society of Hematology (abstract 1538).

Autoantibodies against factor VIII are rare but may cause life-threatening bleeding. Up to 30% of inhibitors may resolve spontaneously, but immunosuppressive drugs with possible serious adverse effects and costly factor replacement are usually required. Rituximab (Rituxan), a humanized monoclonal antibody against CD20-positive B cells, has been reported to be beneficial in certain antibody-mediated autoimmune diseases. We describe here four consecutively treated patients whose acquired factor VIII inhibitors responded rapidly to immunosuppressive regimens that included rituximab administered at 375 mg/m² weekly for 2 to 4 weeks.

ROCKVILLE, Maryland-The US Food and Drug Administration (FDA) has approved the orphan drug Orfadin (nitisinone capsules, Swedish Orphan International) for treating hereditary tyrosinemia type 1 (HT-1), a rare pediatric disease that causes progressive liver failure and liver cancer. In announcing its approval decision, the agency warned that only physicians experienced in treating the disease should prescribe Orfadin. Rare Diseases Therapeutics, Inc., of Nashville, Tennessee, is the drug’s US distributor.

CHICAGO-Highly active anti-retroviral therapy (HAART) has drastically reduced the incidence of primary central nervous system (CNS) lymphoma in HIV-positive individuals at a French hospital and improved survival in HIV-positive patients who have the brain malignancy.

The optimal therapy for advanced-stage follicular lymphoma is unknown. Combination chemotherapy usually induces remissions in most patients; however, nearly all patients eventually progress and there is no clear plateau on disease-free survival analysis. Single-agent treatment with the monoclonal anti-CD20 antibody rituximab (Rituxan) at 375 mg/m² weekly × 4 doses induces response rates of approximately 50% to 60% in patients with relapsed follicular non-Hodgkin’s lymphoma. In some patients, the molecular detection of disease by polymerase chain reaction assay may be eliminated following antibody therapy.

CHICAGO-Fifteen to 20 years ago, treatment of patients infected with Pseudomonas aeruginosa infection after stem cell transplantation was limited to certain beta-lactam and aminoglycoside antibiotics that were active against the organism.

CHICAGO-Two studies presented at the 87th Scientific Assembly and Annual Meeting of the Radiological Society of North America (RSNA) indicate that computer-aided detection (CAD) of lesions on conventional mammography studies is comparable to double-read mammograms, and it produces fewer false-negative results.

BOSTON-Misconceptions about cancer clinical trials are common among trial participants, according to a survey of 205 patients and 61 providers conducted at the Dana-Farber Cancer Institute, Brigham and Women’s Hospital, and Massachusetts General Hospital.

At the 2000 American Society of Hematology meeting, we reported the successful treatment of a patient with acquired hemophilia using rituximab (Rituxan). This patient has required no therapy over the past year and has suffered no further hemorrhages. A June 2001 factor VIII level was 35%, and a factor VIII inhibitor level could not be analyzed due to the high level of factor VIII. Since then, three more patients with acquired factor VIII deficiency have received rituximab therapy at the University of Iowa, and are discussed below.

Immune thrombocytopenic purpura (ITP) in adults is a chronic autoimmune disease characterized by antiplatelet antibody (APA)-mediated thrombocytopenia.

Current evidence suggests that rituximab (Rituxan) works in vivo mainly through complement-dependent cytotoxicity (CDC) and/or antibody-dependent cellular cytotoxicity (ADCC). Here we have investigated the sensitivity of freshly isolated cells obtained from 33 B-cell chronic lymphocytic leukemia (B-CLL), 5 prolymphocytic leukemia (PLL), and 6 mantle cell leukemia (MCL) patients to be lysed by rituximab and complement in vitro.

Hairy cell leukemia (HCL) is an indolent B-cell neoplasm that strongly expresses CD20. Despite initial very high response rates with cladribine (Leustatin), many patients ultimately relapse.

BETHESDA, Maryland-Merck & Co. will use a worldwide research network organized and funded by the National Institute of Allergy and Infectious Diseases (NIAID) to test promising HIV vaccines it develops.

ORLANDO-A multicenter, prospective study has shown that anemia is an independent risk factor predicting decreased survival in HIV-infected women and that highly active antiretroviral therapy (HAART) helps resolve anemia in this population group.

WASHINGTON-A National Academy of Sciences (NAS) committee expects to issue a report in June on terrorism that will provide the federal government with a road map for the use of science and technology in all aspects of counterterrorism, Richard D. Klausner, MD, former National Cancer Institute (NCI) director, told ONI.

Tositumomab/iodine-131 tositumomab (Bexxar) is a novel active agent against CD20-positive lymphoma. There is a paucity of data examining the tolerance and outcome of hematopoietic stem cell transplantation (HSCT) for relapse after tositumomab/iodine-131 tositumomab.